MX377864B - Composición de antígeno para detectar enfermedad de chagas. - Google Patents

Composición de antígeno para detectar enfermedad de chagas.

Info

Publication number
MX377864B
MX377864B MX2017005650A MX2017005650A MX377864B MX 377864 B MX377864 B MX 377864B MX 2017005650 A MX2017005650 A MX 2017005650A MX 2017005650 A MX2017005650 A MX 2017005650A MX 377864 B MX377864 B MX 377864B
Authority
MX
Mexico
Prior art keywords
cruzi
composition
polypeptides
chagas disease
antigen composition
Prior art date
Application number
MX2017005650A
Other languages
English (en)
Other versions
MX2017005650A (es
Inventor
Barbara Upmeier
Christian Scholz
Dieter Roessler
Peter Muench
Toralf Zarnt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017005650A publication Critical patent/MX2017005650A/es
Publication of MX377864B publication Critical patent/MX377864B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición de polipéptidos adecuados para detectar anticuerpos contra Trypanosoma cruzi (T. cruzi) en una muestra biológica aislada que consiste de tres polipéptidos 1F8, JL7 y Cruzipain. Es también parte de la invención un método de producción de una composición soluble e inmunorreactiva de los polipéptidos adecuados para detectar los anticuerpos contra T. cruzi, utilizando la composición de los polipéptidos. Además, la invención se refiere a los métodos para detectar anticuerpos específicos para T. cruzi en una muestra aislada, en donde una composición de los polipéptidos de T. cruzi es utilizada así como un kit de reactivos que comprende la composición de los polipéptidos de T. cruzi.
MX2017005650A 2014-11-06 2015-11-04 Composición de antígeno para detectar enfermedad de chagas. MX377864B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192004.1A EP3018479A1 (en) 2014-11-06 2014-11-06 Antigen composition for detecting Chagas disease
PCT/EP2015/075691 WO2016071392A1 (en) 2014-11-06 2015-11-04 Antigen composition for detecting chagas disease

Publications (2)

Publication Number Publication Date
MX2017005650A MX2017005650A (es) 2017-06-29
MX377864B true MX377864B (es) 2025-03-10

Family

ID=51932184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005650A MX377864B (es) 2014-11-06 2015-11-04 Composición de antígeno para detectar enfermedad de chagas.

Country Status (7)

Country Link
US (1) US10094828B2 (es)
EP (2) EP3018479A1 (es)
JP (1) JP6763855B2 (es)
CN (1) CN107003309B (es)
ES (1) ES2705429T3 (es)
MX (1) MX377864B (es)
WO (1) WO2016071392A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018479A1 (en) * 2014-11-06 2016-05-11 Roche Diagniostics GmbH Antigen composition for detecting Chagas disease
US12188063B2 (en) 2019-02-08 2025-01-07 Institute Of Science Tokyo Enzymatic mutant suitable for homogeneous immunoassay method
CN111751416A (zh) * 2020-07-03 2020-10-09 福建中医药大学 一种新型的美洲大蠊多肽快速检测方法
WO2024229330A1 (en) * 2023-05-03 2024-11-07 Vida Pharmacal Inc. Modified chimeric antigens ibmp 8.1 and 8.3 for the detection and diagnosis of trypanosoma cruzi
CN121049504A (zh) * 2025-09-03 2025-12-02 郑州安图生物工程股份有限公司 用于克氏锥虫抗体检测的试剂盒

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0976763B1 (en) * 1998-07-30 2003-11-05 Innogenetics N.V. Antigens and immunoassays for diagnosing Chagas' disease
PE20050942A1 (es) 2003-12-04 2005-11-10 Louis V Kirchhoff Polipeptidos recombinantes para diagnosticar la infeccion con el trypanosoma cruzi
EP2182979A4 (en) 2007-07-30 2010-09-08 Univ Georgia DIAGNOSTIC ASSAY FOR AN INFECTION WITH TRYPANOSOMA CRUZI
WO2010142829A1 (es) * 2009-06-12 2010-12-16 Consejo Superior De Investigaciones Científicas (Csic) Método de obtención de datos útiles para el diagnóstico diferencial de la enfermedad de chagas, y para evaluar la respuesta al tratamiento
EP3018479A1 (en) * 2014-11-06 2016-05-11 Roche Diagniostics GmbH Antigen composition for detecting Chagas disease

Also Published As

Publication number Publication date
EP3215848A1 (en) 2017-09-13
US20170248597A1 (en) 2017-08-31
MX2017005650A (es) 2017-06-29
EP3215848B1 (en) 2018-10-10
CN107003309A (zh) 2017-08-01
ES2705429T3 (es) 2019-03-25
US10094828B2 (en) 2018-10-09
EP3018479A1 (en) 2016-05-11
CN107003309B (zh) 2020-05-19
WO2016071392A1 (en) 2016-05-12
JP2017534055A (ja) 2017-11-16
JP6763855B2 (ja) 2020-09-30
BR112017006569A2 (pt) 2018-01-16

Similar Documents

Publication Publication Date Title
AR107078A1 (es) Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
MX2019008221A (es) Anticuerpo anti-gpc3.
MX2017013777A (es) Metodo para el tratamiento de cancer.
MX387936B (es) Metodo para la cuantificacion de huevos de parasitos en las heces.
MX2017005650A (es) Composicion de antigeno para detectar enfermedad de chagas.
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
AR099465A1 (es) Anticuerpos anti-jagged1 y métodos de uso
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
CL2016001867A1 (es) Sistema y dispositivo para la generación de alto rendimiento de gotitas y métodos de uso combinatorios.
BR112016010822A2 (pt) anticorpos específicos para fcrn
AR090884A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
MX2020003523A (es) Deteccion de dimetilarginina simetrica.
BR112017023131A2 (pt) anticorpos anti- fcrn
WO2015011282A3 (en) Method for identifying modulators of bcrp/abcg2-mediated atp release and use of said modulators for treating diseases
BR112016008477A2 (pt) Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
MX2019002578A (es) Métodos de detección de la expresión del ligando 1 de muerte programada por célula y usos de los mismos.
BR112017010078A2 (pt) composições, dispositivos e métodos de teste de sensibilidade de ibs
EP3100046A4 (en) Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit
IL250867A0 (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
NI201600127A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES FORMULACIONES Y USO DE ESTA.
WO2013181576A3 (en) Methods of evaluating and making biologics
BR112016028838A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer